Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Yissum Introduces a Pioneering Vaccine Against CME

Published: Thursday, December 13, 2012
Last Updated: Thursday, December 13, 2012
Bookmark and Share
Results showing the effectiveness of the vaccine in dogs were recently published in the journal Vaccine.

Canine monocytic ehrlichiosis (CME) is a major, potentially fatal, tick-borne dog disease prevalent worldwide.

No commercial vaccine for the disease is currently available and tick control is the main preventive measure against the disease.

Now, Yissum Research and Development Company of the Hebrew University of Jerusalem, introduces a vaccine against CME, which was developed by Professors Shimon Harrus and Gad Baneth, from the Koret School of Veterinary Medicine, Faculty of Agricultural, Food and Environmental Quality Sciences at the Hebrew University of Jerusalem.

The vaccine has proven effective in an experimental study in dogs, which was recently published in the prestigious journal Vaccine.

Profs. Harrus and Baneth developed the vaccine from a proprietary attenuated strain of Ehrlichia canis, the bacteria that causes CME. The efficiency of the attenuated strain as a vaccine was assessed on 12 dogs, which were divided into three groups.

Four dogs were inoculated (vaccinated) with the attenuated Ehrlichia strain twice, four dogs only once and the last group of four dogs served as the control group.

The vaccinated dogs showed no clinical signs after the inoculation, suggesting that the novel vaccine is safe for use and does not induce adverse effects.

When the dogs were infected with a virulent Ehrlichia field strain, the control dogs all developed a severe disease, whereas only three of the eight vaccinated dogs presented mild transient fever and the rest remained healthy.

"Canine monocytic ehrlichiosis is a serious dog disease that can lead to death. Current treatment includes supportive care, and a harsh and lengthy antibiotic treatment, which may not be effective in chronic infections. The vaccine developed by Profs. Harrus and Baneth is the first vaccine to prove effective against this disease," said Yaacov Michlin, CEO of Yissum.

Michlin continued, "The current lack of vaccine for CME, the growing awareness of the market and the growing market needs make this invention particularly attractive, and Yissum is currently looking for commercial partners for further development and commercialization purposes."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Scientists Uncover Why Hepatitis C Vaccine is Difficult to Make
Scientists have uncovered one reason why a successful hepatitis C vaccine continues to be elusive.
Antibodies from Ebola Survivors Neutralize Virus, Protect Lab Mice
Scientists discover antiboides generated from the blood of Ebola survivors can strongly combat the virus in the lab.
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
Sustained SIV Remission Achieved in Monkeys
Experimental treatment boosts monkey immune system to force SIV into sustained remission.
Fighting Cancer with Immune Response
New treatment elicits two-pronged immune response that destroys tumors in mice.
Nanoparticles Offer Promising Platform for Flavivirus Treatment
New nanoparticle effectively vaccinated mice against one dengue strain and could be created to target all four.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
The Power Of Orthogonality In Assessing The Stability Of Biopharmaceuticals
By utilizing orthogonal techniques, researchers can maximize the secure application of all analytical results generated.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos